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Abstract
Despite being the second most common form of neurode-
generative dementia, dementia with Lewy bodies (DLB) is 
under-recognized and carries a worse prognosis than other 
subtypes of the condition. Cognitive impairment is a cardi-
nal feature of all types of dementia and DLB presents with a 
distinct profile with deficits in attention, executive function, 
and visuoperceptual abilities. This difference from Alzheim-
er’s disease and the common presence of neuropsychiatric 
symptoms may lead to challenges in predicting cognitive 
decline in this patient population. Firstly, the diagnosis of 
DLB is often delayed in clinical practice leading to variability 
from which time point in the disease course cognitive de-
cline is measured. Secondly, the most frequently used mea-
surement tools for cognitive difficulties focus on memory 
and naming rather than the domains affected by DLB. While 
there is now largely a consensus which tools are useful in di-
agnosing DLB, their validity in assessing deteriorating cogni-
tion is less clear. Thirdly, the presence of fluctuating cogni-
tion, the propensity to develop delirium episodes, as well as 
difficulties in distinguishing the two entities in clinical prac-
tice make it difficult to predict the disease course. Sleep dis-
turbances are likely to influence cognitive decline but re-
quire further study  in patients within established DLB. 
Fourthly, as in most cases of dementia, neuropathological 
comorbidities are frequently present in DLB. While the influ-
ence of Alzheimer’s pathology on cognitive decline in DLB is 
comparatively well understood, the impact of other patholo-
gies remains unclear. The recent definition of research crite-
ria for mild cognitive impairment in DLB could facilitate ear-
lier diagnosis and more structured follow-up. Assessment 
tools measuring cognitive domains predominantly affected 
in DLB need to be more consistently used in longitudinal 
studies and clinical practice, as well as concurrent measures 
of fluctuations in cognition. Greater availability of biomark-
ers and digital healthcare solutions can play an important 
role in enabling more accurate monitoring and prediction of 
cognitive decline in DLB. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Dementia with Lewy bodies (DLB) is the second most 
common form of neurodegenerative dementia. While 
neuropathological case studies report incidences of 15–
20% [1], this is considerably lower in routine clinical ser-
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vices, often below 5%, with large geographical variations 
[2]. Compared to other forms of dementia, including 
Alzheimer’s disease (AD), DLB is known to have a less 
favourable prognosis in a number of domains including 
an almost 2 years earlier mortality, higher rates of hospi-
talisation and institutionalization, more frequent epi-
sodes of delirium, lower quality of life, and higher care-
giver burden and healthcare costs [3–10]. Less certainty 
exists in relation to cognitive decline in DLB despite a 
progressive cognitive impairment being a cardinal fea-
ture of all dementias. Although several current studies 
[11, 12] suggest an accelerated cognitive decline com-
pared to AD, the most recent meta-analysis found no dif-
ference between DLB and AD [13]. This review aims to 
outline challenges in predicting cognitive decline in DLB, 
to provide potential solutions for the practicing clini-
cians and to set future research directions (see Table 1 for 
an overview).
Challenges due to a Delayed Diagnosis of Dementia 
with Lewy Bodies
The prevalence of DLB amongst dementia subtypes di-
agnosed in memory services is about a quarter to one-
third of what be expected from autopsy studies and DLB 
thereby seems substantially under-recognized [2]. A de-
lay in DLB diagnosis is well-described in the literature: in 
the USA, more than 1 year was needed to establish the 
correct diagnosis of DLB for almost 50% of patients [14]. 
Similarly, in the UK, it took on average 1.2 years to arrive 
at a diagnosis of DLB from the initial appointment and 
more imaging and clinical assessments were needed than 
for patients with non-DLB diagnoses [15]. The impact of 
this delay in diagnosis on predicting cognitive decline is 
not clear. This, however, leads to the absence of a consis-
tent point from which deterioration could be measured. 
Patients with DLB and AD are in most studies diagnosed 
Table 1. Overview of challenges, clinical considerations, and research directions
Challenge Clinical considerations Research directions
Delayed diagnosis of DLB Proactively diagnose MCI and consider the possibility of 
Lewy body pathology
Prospective studies on how patients with MCI-LB 
progress to dementia
Severe presentations of new-onset mental illness in old age 
could be in the context of (prodromal) DLB
Monitoring of cognitive decline in those who have been 
diagnosed with DLB following a previous MCI or MCI-
LB diagnosis
Tests used to diagnose DLB and 
to measure change over time
Use tools assessing cognitive domains predominantly 
affected in DLB (e.g., Montreal Cognitive Assessment 
(MoCA)) as screening tool and for follow-up assessments
Larger scale observational studies using the MoCA or a 
similar tool
Further studies to assess decline in individual cognitive 
domains
Fluctuating cognition, delirium 
episodes, and sleep disturbances
When assessing cognition, simultaneously also assess for 
fluctuations, ideally using a structured tool (e.g. Clinician 
Assessment of Fluctuation scale or the Mayo Fluctuation 
Composite Score)
Develop a better understanding of the longitudinal 
course of fluctuations in DLB
Suspect underlying DLB in certain delirium presentations 
(no trigger, prolonged or recurrent, followed by progressive 
cognitive decline) and investigate accordingly
Examinations of the interaction between the processes 
underlying delirium and DLB neuropathology
Routinely assess patients with DLB for REM sleep 
behaviour disorder and other sleep disturbances
Assess the impact of REM sleep behaviour disorder, 
insomnia, and daytime sleepiness (as well as their 
treatments) on cognitive decline in cohorts of patients 
with established DLB
Neuropathological co- and 
multi-morbidity
Establish clinical features of possible comorbid AD (using 
cognitive testing, CSF, or neuroimaging)
Larger clinico-pathological studies exploring the relative 
influence of amyloid-beta, tau, alpha-synuclein, 
cerebrovascular damage, TDP-43, and hippocampal 
sclerosis on cognitive decline and the general clinical 
picture
DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; MCI, mild cognitive impairment; MCI-LB, mild cognitive impairment with Lewy bodies; 
MoCA, Montreal Cognitive Assessment; REM, Rapid Eye Movement; CSF, cerebrospinal fluid.
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with similar Mini-Mental State Examination scores 
(MMSE) [16], whereby scores in DLB patients are often 
slightly higher than in AD cohorts. A meta-analysis of 
survival data showed that differences in survival time 
were not explained by MMSE score at the time of diagno-
sis [8]. However, a study which measured survival from 
fixed MMSE score points of 20 and 17 showed that DLB 
had a shorter survival than AD when following up from 
each of these score points [17]. This could possibly indi-
cate that at a higher MMSE score, the neurodegenerative 
process could already be further advanced in DLB. The 
variable ways in which DLB can present poses a challenge 
for clinical services. In a recent study of 251 patients di-
agnosed with DLB in a UK mental health and dementia 
care service, the most common early complaints were 
memory loss, but also hallucinations and low mood [18].
Early correct diagnosis of DLB remains an important 
challenge and an important step forward is the recent def-
inition of research criteria for mild cognitive impairment 
(MCI) in DLB (MCI-LB) [19]. As in other already estab-
lished diagnostic standards for MCI in neurodegenera-
tive conditions, the triad of a subjective cognitive con-
cern, an objective impairment in at least one cognitive 
domain, and largely preserved independent functioning 
needs to be met [20]. The cognitive impairment can be in 
any domain, but in the context of DLB, it is more likely to 
be associated with visuospatial, attentional, or executive 
deficits. For a diagnosis of MCI-LB, the authors propose 
that additional core features of DLB (fluctuating cogni-
tion, recurrent visual hallucinations, REM sleep behav-
iour disorder (RBD), at least one Parkinsonian motor 
sign) and/or proposed biomarkers (reduced dopamine 
transporter uptake in basal ganglia demonstrated by 
SPECT or PET, polysomnographic confirmation of REM 
sleep without atonia, and reduced meta-iodobenzylgua-
nidine uptake on myocardial scintigraphy) need to be 
present [19]. Depending on the number of symptoms and 
biomarkers elicited, the research criteria support the di-
agnosis of either “probable” MCI-LB (at least 2 core fea-
tures or one core feature and at least one biomarker pres-
ent) or “possible” MCI-LB (only one core feature or bio-
marker present).
Another important concept is “mild behavioural im-
pairment,” which was developed mirroring MCI to detect 
behavioural changes occurring in later life, which do not 
meet the criteria for a major psychiatric disorder or de-
mentia [21]. Neuropsychiatric symptoms, even if mild 
and occurring in the absence of an obvious cognitive im-
pairment, have been shown to be associated with an in-
creased dementia risk [22, 23]. Although not formally op-
erationalized, a psychiatric-onset DLB has been proposed 
[19], whereby more severe new-onset psychiatric presen-
tations, as late-onset major depressive disorder and late-
onset psychosis should raise the suspicion of underlying 
Lewy body pathology. In these presentations, cognitive 
testing and evaluation of the patient’s performance are 
challenging, both due to overlapping psychiatric symp-
toms and the propensity of patients with DLB to fluctuate 
in presentation. It has been shown that careful observa-
tion of the phenomenology (DLB presenting with more 
visual hallucinations and less paranoia than very-late-on-
set schizophrenia-like psychosis), and the neuropsycho-
logical profile (DLB presenting with prominent visuospa-
tial deficits) can aid differential diagnosis between neuro-
degenerative and functional psychosis [24]. A higher 
frequency of hypersensitivity to any psychotropic medi-
cation and autonomic failure (ventilatory response to hy-
percapnia) can further predict DLB in those with late-
onset depression [25]. In clinical reality, the use of bio-
markers suggested as useful in MCI-LB, might supplement, 
or replace, these complex observations, but their clinical 
and economic value will need to be demonstrated [19, 
26].
Overall, the variation of the time point and severity at 
which DLB is diagnosed makes it difficult to establish a 
clear baseline from which further decline can be moni-
tored. The recent establishment of research criteria for 
MCI-LB and the increasing availability of biomarkers are 
important steps to facilitate earlier diagnosis and to im-
prove monitoring of cognition. In cohorts which have 
been identified as at risk prior to receiving the diagnosis 
of dementia, there might be less heterogeneity between 
patients when the diagnosis is established. This should 
make it easier to synchronize cognitive trajectories and 
allow more coherent prediction of progression of cogni-
tive decline [27].
Challenges with Structured Cognitive Tests Used 
to Diagnose Dementia with Lewy Bodies and to 
Measure Change Over Time
In contrast to AD, which is primarily characterised by 
impaired memory and language, there is a higher occur-
rence of difficulties in attentional, executive, and vi-
suoperceptual domains in DLB [28]. As DLB and demen-
tia in Parkinson’s disease (PDD) have an overlapping 
cognitive profile, recommendations regarding screening 
for PDD are likely to be useful for DLB. The Movement 
Disorder Society review committee recently endorsed 
Tsamakis/MuellerDement Geriatr Cogn Disord 2021;50:1–84
DOI: 10.1159/000515008
[29] the Montreal Cognitive Assessment (MoCA) [30], 
Mattis Dementia Rating Scale Second Edition (DRS-2) 
[31], and the PD-Cognitive Rating Scale (PD-CRS) [32] 
for cognitive screening in Parkinson's disease. Not rec-
ommended were the scales most frequently used in clini-
cal dementia services, the Mini-Mental State Examina-
tion (MMSE) [16] and the Adenbrooks’s Cognitive Ex-
amination (ACE-R/ACE-III) [33, 34]. The MMSE is 
considered unsuitable as it primarily tests cortical aspects 
of cognition, as memory and language, which are fre-
quently preserved in PDD or DLB (also subsumed as 
Lewy body dementias; LBD), with insufficient testing of 
visuospatial and executive function [29]. The ACE-R/
ACE-III [33] has good psychometric properties and as-
sesses  visuospatial function to a larger degree but has in-
complete coverage of executive function, limited to only 
fluency tasks [29]. In contrast to the Mattis Dementia 
Rating Scale (DRS-2) and the MMSE, the MoCA has been 
shown to predict progression from MCI to PDD [35] as 
well as sensitivity to change over time in Parkinson’s dis-
ease without dementia [36]. In the latter longitudinal 
study of 102 patients with PD, lower MoCA scores, pos-
tural instability and gait disturbance, and depressive 
symptoms at baseline were associated with a higher risk 
of cognitive decline [36]. However, little is known how 
structured tests can evaluate cognitive decline in those 
with Lewy body disease who have already reached the de-
mentia stage. The rate of cognitive decline in LBD has 
been assessed in a number of longitudinal studies, largely 
using the MMSE, and the latest meta-analysis found sim-
ilar decline in LBD and AD [13]. It has been speculated 
that this lack of difference might be grounded in the 
MMSE being not sensitive enough in registering cogni-
tive deficits specific to LBD [37]. Differences in the rate 
of change between MMSE and MoCA were evaluated 
over 1 year in fourteen patients with DLB: no significant 
difference between the decline on MMSE (0.98-point de-
cline) and the MoCA (1.04-point decline) was detected, 
with a trend of MoCA being more sensitive in identifying 
cognitive decline in patients with a milder cognitive im-
pairment [37]. This underlines that larger follow-up stud-
ies regularly applying MoCA over several years are need-
ed to elucidate its usefulness for cognitive prognostica-
tion in DLB.
Visuospatial functioning has been identified as poten-
tial predictor of faster cognitive and functional decline in 
DLB [38, 39]. However, a more recent study of 67 patients 
with DLB followed for up to 4 years [40] found no sig-
nificant association between low visuospatial scores at 
baseline and faster cognitive decline (measured by 
MMSE) or progression of dementia severity. The same 
study assessed cognitive decline on a number of domain-
specific tests in patients with DLB comparatively to 119 
patients with AD [40]. A difference in the rate of cognitive 
decline between DLB and AD was only detected in the 
Trail Making Test A (TMT-A), which assesses visual 
scanning, psychomotor speed, and attention by asking 
the participant to draw a line to connect consecutive 
numbers from 1 to 25 [41]. Older studies also identified 
that patients with DLB declined slower in recognition 
memory and recall, but more rapidly in verbal fluency 
than those with AD [42–44].
Overall, assessment of cognition in DLB should not 
rely on tests predominantly assessing language and mem-
ory, and the MoCA appears to be a useful tool to detect 
cognitive difficulties and progression to dementia. Larger 
scale evaluations are required in patients who have al-
ready been diagnosed with DLB, both to determine Mo-
CA’s (or similar tests') performance and domain-specific 
decline.
Challenges due to Fluctuating Cognition, Delirium 
Episodes, and Sleep Disorders
Fluctuations are one of the core features of DLB and 
present in the majority of patients [45]. The term is used 
to describe spontaneous variations of cognitive abilities, 
alertness, or arousal [28]. Importantly those periods of 
impaired cognition occur on a spectrum between very 
marked changes (often described as delirium-like) to 
mild episodes of reduced responsiveness and alternate 
with close-to-normal cognitive performance [46]. Peri-
ods of apparent lucidity may be triggered by a novel en-
vironment or formal assessment, for example, in an out-
patient clinic, and this could lead to improved perfor-
mance in cognitive testing. The duration and pattern of 
fluctuations can be highly variable, from very short (last-
ing minutes to hours) to longer episodes (lasting days). 
Hence, these are unlikely to be noted by the clinician dur-
ing a single clinical encounter but could potentially lead 
to differing outcomes, and possibly improvements, in 
consecutive assessments. Fluctuations do not tend to fol-
low a diurnal rhythm and several forms of fluctuations 
(both in terms of duration and severity) may occur in the 
same patient [46]. This is also reflected in the longitudinal 
assessment of cognition in patients with DLB over time. 
Patients with Lewy body pathology have been described 
to have a greater variation across annual mean cognitive 
decline [47], and in the largest clinical study assessing 
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cognitive decline in DLB, recruiting more than 800 pa-
tients, 18% of patients had an improved MMSE score 2 
years after baseline [12].
Delirium (or acute confusional state) has been de-
scribed as an early feature of DLB, and delirium-onset 
DLB has been proposed in the research criteria for pro-
dromal DLB [19, 48]. The authors suggest suspecting pro-
dromal DLB when no adequate trigger for the delirium 
episode is found, when the delirium is recurrent or pro-
longed, and/or when the delirium leads to progressive 
cognitive decline [19]. While the higher occurrence of de-
lirium in the early/prodromal/pre-diagnosis stage is well-
described, recent research has also shown that patients 
with DLB remain at an increased risk of delirium com-
pared to those with AD after a diagnosis of dementia is 
established [5]. This could reflect a misinterpretation of 
marked fluctuations (with clouding of consciousness and 
confusion) as delirium, DLB patients’ increased vulner-
ability for developing delirium episodes, or a combina-
tion of both factors [19].
In addition to potentially affecting the outcome of cog-
nitive testing, delirium episodes occurring in those with 
established dementia are known to accelerate cognitive 
decline. Cognitive decline triggered by delirium has been 
shown to be more rapid than can be explained by the neu-
rodegenerative disease or the processes driving the de-
lirium alone [49]. However, patients with Lewy body pa-
thology form a minority in studies examining the interac-
tion between delirium and neurodegeneration, and their 
trajectory following delirium episodes remains unclear. It 
is important to recognise that a delirium episode might 
be in the context of (potentially undiagnosed) DLB, to ap-
ply caution when considering treatment with antipsy-
chotic medications, which are associated with severe ad-
verse outcomes in DLB [4, 19].
While disturbed sleep is an established risk factor for 
cognitive decline and development of dementia [50], and 
there appears to be a particularly increased risk for those 
with RBD to develop an alpha-synucleinopathy as DLB 
[51], less is known about how sleep disturbances affect 
prognosis in those with an established diagnosis of DLB 
[52]. In all-cause dementia, sleep disturbances are associ-
ated with a poorer prognosis, including a higher frequen-
cy of neuropsychiatric symptoms and worse quality of 
life, as well as more severe cognitive decline [52]. The as-
sociation between dementia and sleep disturbances is 
considered bidirectional, whereby the brain pathology 
can lead to disturbed sleep, and the sleep disturbance to 
accelerated cognitive decline [52]. Considering the strong 
link between RBD and DLB [53], it is likely that these re-
lationships with adverse outcomes are also relevant for 
DLB and proactive identification of difficulties sleeping is 
important in clinical practice [54]. However, studies ex-
plicitly assessing the effect of sleep disturbances in pa-
tients with established DLB are lacking. In addition to 
RBD, there would be value in evaluating the impact of 
insomnia and excessive daytime sleepiness. All 3 are com-
mon in alpha-synucleinopathies [55] but require differ-
ing treatments and might thereby lead to variations in 
cognitive trajectories [52].
Overall, delirium episodes, whether recognised or un-
recognised, as well as potentially overlapping cognitive 
fluctuations, might contribute to the nonlinear, difficult-
to-predict course of cognitive decline in DLB. Concur-
rently assessing cognition and fluctuations using a semi-
quantitative scale (e.g., the Clinician Assessment of Fluc-
tuation scale [56] or the Mayo Fluctuation Composite 
Score [57]) could make it easier to contextualize the cog-
nitive scores and improve prediction of cognitive decline 
in patients with DLB. Sleep difficulties are likely to influ-
ence cognitive decline in DLB. It is important that those 
are recognised in routine practice and their impact on 
cognitive trajectories studied in cohorts of patients with 
established DLB.
Challenges due to Neuropathological Co- and  
Multi-Morbidity
Lewy body pathology is independently linked to cog-
nitive decline [47, 58] and the distribution of Lewy bodies 
in different regions of the brain may influence their effect 
on cognition. Most relevant are probably limbic and neo-
cortical Lewy bodies [47], but brain stem Lewy body pa-
thology might also play a role [59]. It is now recognized 
that most patients with the clinical syndrome of dementia 
have mixed neuropathologies [60]. The impact of Lewy 
body pathology on cognitive loss varies at a person-spe-
cific level depending on additional brain pathologies 
present [58], whereby the most frequently occurring 
overlap with AD pathology (reported in at least two-
thirds of cases of DLB) has an additional effect leading to 
accelerated cognitive decline. While earlier studies de-
tected the AD pathological substrate post-mortem [61, 
62], more recent work used cerebrospinal fluid (CSF) 
analysis [63]. An “Alzheimer’s” CSF pattern with higher 
total-tau and lower amyloid-beta-42 has been linked to 
worse performance in MMSE subtests assessing memory 
and orientation in patients with DLB [64]. Further, ab-
normal CSF amyloid-beta-42 has been shown to be more 
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common in those with medial temporal lobe atrophy on 
MRI scans [65, 66].
However, in Boyle and colleagues’ study [58] on mixed 
pathologies using the Religious Orders Study and the 
Memory and Aging Project, of 143 patients with cortical 
Lewy bodies, only 5 (4%) had pure Lewy body pathology 
(i.e. without additional neuropathologies). Besides AD, 
which was very common comorbidly with Lewy bodies 
(73%), other pathologies also occurred frequently, and at 
a similar rate to other studies [67, 68]. These included 
gross infarcts (34%), microinfarcts (26%), transactive re-
sponse DNA-binding protein 43 (TDP-43, 41%), and 
hippocampal sclerosis (12%). These pathologies were of-
ten detected in combination and more than a third of the 
full cohort of more than 1,000 patients had 4 or more 
concomitant pathologies [58].
Overall, comorbid Alzheimer’s pathology has consis-
tently been implicated in a more rapid cognitive decline 
in patients with DLB, and indicators of AD pathology are 
amnestic impairments in cognitive testing, an “Alzheim-
er’s” CSF patterns and medial temporal lobe atrophy. 
However, the impact of other pathologies on cognitive 
decline in DLB, especially in the context of multiple pa-
thologies, remains unclear and requires further explora-
tion in larger clinico-pathological cohorts [69].
Conclusion
Dementia is a multifactorial condition with highly 
variable disease progression, and this is particularly rel-
evant for DLB [27]. During the disease course of DLB 
numerous complex processes interact and cognitive de-
cline is often determined by several neurodegenerative 
pathologies as well as comorbid physical and mental 
health conditions [70, 71].
Challenges in relation to cognitive prognostication in 
DLB highlighted in this review are: making a timely diag-
nosis and establishing a consistent baseline from which 
decline can be measured, using tests sufficiently assessing 
domains affected by DLB to monitor decline, as well as 
continued awareness of other factors that can affect cog-
nitive performance and considering the interplay be-
tween differing brain pathologies. Further, for patients 
with Parkinson's spectrum disorders, as DLB, access to 
clinics for diagnosis and monitoring can be difficult due 
to motor or neuropsychiatric symptoms [72]. Hence, it 
has been highlighted that remotely collected data can re-
duce the need to commute for these patients while pro-
viding real-time insights into disease progression and 
treatment response [73]. These novel digital healthcare 
solutions could assist in addressing some of the challeng-
es in relation to detecting DLB and monitoring cognitive 
decline [73, 74]. Of particular interest are fluctuations, 
visual hallucinations, and autonomic instability. Remote 
monitoring of thermoregulation or cardiovascular pa-
rameters, as hypotension, could feed into assessments 
leading to an earlier diagnosis. Remote EEG [75] could, 
besides aiding detection of visual hallucinations, also 
measure fluctuations [73], one of the main challenges in 
predicting cognitive decline. Further research is needed 
to validate tools like the MoCA [30] in longitudinal stud-
ies, to determine the influence of delirium episodes on the 
disease course of DLB, and to develop a more fine-grained 
definition of clinico-pathological phenotypes potentially 
diagnosable through biomarkers.
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